Mindful Innovation Bringing Hope to Patients

Developing new treatments to improve the lives of patients and families affected by epilepsy and neuropsychiatric disorders.

Our Pledge to Patients

Marinus Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings.

Our Science & Pipeline

Postpartum Depression

Striving to Support Strong Mother-Baby Bonds

Developing therapies with the potential to address postpartum depression more quickly and in an outpatient setting.

Learn More

Orphan Epilepsies

Aspiring to Give Children Seizure-Free Days

Ganaxolone offers the potential to safely decrease seizure frequency in children with refractory epilepsy.

Learn More

Why We Work

To make a difference in the lives of patients and their families.

  • Violet

    “She spends time at the park and beach, works hard in school, loves playing with her little brother, and making new friends.”

  • Artwork by G

    “Meet our special little guy who enjoys creating beautiful pieces of art with his mommy to help raise awareness for CDKL5.”

  • Sloan

    “Sloan surprises us with new skills every day and is the sweetest, funniest, spunkiest little girl our family could have been blessed to have.”

  • Artwork by Ava

    This artwork was made by young Ava.

  • Kiera

    “She is a vibrant and intelligent young lady who has a wonderful sense of humor, love for music, dancing, and the moon and stars.”

  • Amanda

    “We call our daughter Amazing Amanda, and quite simply… she IS. Her strength and tenacity wows me; she is my hero!”

Follow Us on Twitter

The patient story section of our website profiles the courageous families living with rare CNS disorders, and fuels our passion to find new therapies: https://t.co/mTEHxkQVBx

Do you have a story to share? Send us a private message and we'd be happy to talk with you.

CDKL5 disorder mainly affects girls, but there are many boys who have been diagnosed worldwide. #TheMarigoldStudy is a clinical trial for boys and girls who have tested positive for the CDKL5 gene mutation: https://t.co/TA1LVZbfNL

After #WorldBreastFeedingWeek, we're encouraging new mothers to understand the relationship between #breastfeeding and #PPD at @Bf_USA https://t.co/OKKTkTTpLn

Sign Up For Updates

Receive periodic updates on program progress, clinical trials, and other timely information.